https://orcid.org/0000-0003-2251-3408
About the Authors
- Norio Miyamura
-
Roles Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing
Affiliation Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America
- Chisato M. Yamazaki
-
Roles Investigation
Affiliation Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Center at Houston, Houston, Texas, United States of America
- Yasuaki Anami
-
Roles Investigation
Affiliation Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Center at Houston, Houston, Texas, United States of America
- Kyoji Tsuchikama
-
Roles Supervision, Writing – review & editing
* E-mail: kyoji.tsuchikama@uth.tmc.edu (KT); ks3120@cumc.columbia.edu (KNS)
Affiliation Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Center at Houston, Houston, Texas, United States of America
- Kazuki N. Sugahara
-
Roles Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing
* E-mail: kyoji.tsuchikama@uth.tmc.edu (KT); ks3120@cumc.columbia.edu (KNS)
Affiliation Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America
Competing Interests
“K.N.S. is a co-founder of Cend Therapeutics, Inc (now Lisata Therapeutics, Inc), and has ownership interest in the company. K.N.S. is an inventor on a patent application relevant to this article (WO2009126349). C.M.Y., Y.A. and K.T. are named inventors on the patent applications (WO2018218004A1, US11629122B2, EP3630189A4 and WO2023122587A3) relating to the linker technologies described in this article. K.T. is a co-founder of and holds equity in CrossBridge Bio. This does not alter our adherence to PLOS ONE policies on sharing data and materials. N.M. has no competing interests to declare.” WO2009126349: Methods and compositions related to internalizing RGD peptides WO2018218004A1: Linkers for antibody drug conjugates US11629122B2: Linkers for antibody drug conjugates EP3630189A4: Linker for antibody medicinal conjugates WO2023122587A3: Tripeptide linkers and methods of use thereof.